Vyne Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

YARROW BIOSCIENCE

17/03/2022 13:14

* Vyne Therapeutics Inc  VYNE.OQ  reported a quarterly
adjusted
loss of 20 cents​​ per share for the quarter ended in December.
The mean expectation of six analysts for the quarter was for a
loss of 24 cents per share.
    * Revenue fell 46.5% to $2.29 million from a year ago; 
analysts
expected $4.13 million. 
    * Vyne Therapeutics Inc's reported EPS for the quarter was a
loss
of 22 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Vyne Therapeutics Inc shares had fallen by 43.6% this
quarter.
    * The company reported quarterly net income of $11.57
million.
    * Wall Street's median 12-month price target for Vyne
Therapeutics
Inc is $5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 17 at 01:13 p.m.  ​All
figures in US dollars unless otherwise stated